🔎 Trials Near Me

Home › Hodgkin Lymphoma

Hodgkin Lymphoma clinical trials recruiting in the U.S.

63 studies for Hodgkin Lymphoma are recruiting participants at sites across the United States.

Hodgkin lymphoma is a type of lymphoma, cancer of the lymph system. It is serious but can usually be cured if found and treated early. Learn more.

Cities with the most studies

By state

Recently updated studies

Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma

RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT05272384

Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols

RecruitingObservational study
Ages 18 to 120 · All sexes · Updated Nov 12, 2026 · NCT02682667

Patient-Reported Outcomes and Quality of Life in Adult and Pediatric Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)

RecruitingObservational study
Ages 8 and older · All sexes · Updated Nov 10, 2026 · NCT06098430

Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT03618550

A Phase 1 of CTX-8371 in Patients With Advanced Malignancies

RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06150664

Auto Stem Cell Transplant for Lymphoma Patients

RecruitingPhase 2
Up to age 75 · All sexes · Updated Nov 4, 2026 · NCT03125642

Personalized NK Cell Therapy in CBT

RecruitingPhase 2
Ages 15 to 80 · All sexes · Updated Nov 2, 2026 · NCT02727803

Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma

RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 2, 2026 · NCT03681561

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

RecruitingObservational study
Ages 0 to 38 · All sexes · Updated Oct 29, 2026 · NCT06131801

Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer

RecruitingObservational study
Ages 18 to 120 · All sexes · Updated Oct 28, 2026 · NCT01137643

Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors

RecruitingPhase 1
7 Months – 21 Years · All sexes · Updated Oct 27, 2026 · NCT02508038

Tissue Collection for Studies of Lymph Cancer

RecruitingObservational study
Ages 18 and older · All sexes · Updated Oct 26, 2026 · NCT01676805

CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant

RecruitingPhase 2Healthy volunteers welcome
Ages 18 to 75 · All sexes · Updated Oct 23, 2026 · NCT06059391

AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion

RecruitingPhase 2
1 Day – 30 Years · All sexes · Updated Oct 23, 2026 · NCT04099966

ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma

RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 20, 2026 · NCT07021989

Wisconsin Ginseng for Decreasing Cancer Related Fatigue

RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 20, 2026 · NCT06395441

AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.

RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Oct 13, 2026 · NCT06137144

Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies

RecruitingObservational study
Ages 18 and older · All sexes · Updated Oct 13, 2026 · NCT00131014

Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas

RecruitingPhase 1
Ages 12 to 75 · All sexes · Updated Oct 2, 2026 · NCT06176690

CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)

RecruitingPhase 1
Ages 12 to 75 · All sexes · Updated Oct 2, 2026 · NCT02917083

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT03418038

A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL

RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT05615636

From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.